Centessa Pharmaceuticals (NASDAQ:CNTA) stock experienced a significant decline of 7.2% during mid-day trading on Monday, reaching a low of $9.45. The stock had previously closed at $10.18. The trading volume was approximately 69% lower than the average daily volume, with 96,853 shares traded. Wall Street analysts have given the stock a consensus rating of 'Moderate Buy' with a target price of $10.00. Centessa Pharmaceuticals has a market capitalization of $957.57 million and a price-to-earnings ratio of -6.51. The company reported earnings per share (EPS) of ($0.38) for the quarter, surpassing the consensus estimate of ($0.41) by $0.03. Insider Karen M. Anderson sold 51,160 shares of Centessa Pharmaceuticals stock at an average price of $11.88, totaling $607,780.80. Institutional investors currently own 82.01% of the company's stock.
Andrea Sabens, the Chief Accounting Officer of Lantheus Holdings, Inc. (NASDAQ:LNTH), sold 341 shares of the company's stock on June 13th. The shares were sold at an average price of $79.77, resulting in a total value of $27,201.57. Following the sale, Sabens now owns 62,557 shares of Lantheus stock, valued at $4,990,171.89. This sale was disclosed in a document filed with the Securities & Exchange Commission. Sabens has also sold 341 shares of Lantheus stock on May 13th and April 15th. Lantheus Holdings, Inc. is a medical equipment provider that develops, manufactures, and commercializes diagnostic and therapeutic products for heart, cancer, and other diseases. The company has a market capitalization of $5.73 billion and a price-to-earnings ratio of 12.10. Lantheus stock traded at $82.63 on June 17th.